Hope restored: The critical role that Minimal Residual Disease can play in blood cancer patient care

Nitin Sood

Nitin Sood

Chief Commercial Officer, MRD
Connect:

Nitin Sood is the Chief Commercial Officer, MRD, of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Nitin has a wealth of experience in commercial expansion, product development and building successful businesses at leading life science and diagnostic companies, with a focus on the application of NGS in medicine and research. Most recently, he was Sr. Vice President of Product at Guardant Health where he led the commercial expansion of the company’s oncology portfolio to cover advanced and early-stage cancers, including the launch of Guardant Reveal for solid tumor MRD. 

Prior to that he was CEO of NuGEN, a leader in NGS sample prep. His experience also includes leading global businesses at PerkinElmer and Agilent Technologies, where he held GM roles spanning a portfolio of products in genomics, pathology, and pre-clinical research. He holds master’s degrees in both computer science and molecular biology from Ball State University and Delhi University.